Accordingly, Luo et al92 observed that PD-1 blockade exposure was not associated with increased risk of severity of COVID-19 in patients with lung cancer.89 92 Notably, ICI may even represent an effective approach in the management of COVID-19 patients without cancer.71 73 76 79 Additionally, a combination of ICI with an anti-IL-6 antibody is an attractive approach to reduce the risks of both irAEs and possible cytokine excess frequently observed in severe COVID-19 cases.93 A study following this strategy is currently recruiting patients. This evidence concerns the gene PDCD1 and COVID-19.